ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma
PeerJ · 17.06.2026 · 14 · e21347
DOI: 10.7717/peerj.21347 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, online erschienen am 17.06.2026. Verfasst von Wangyu Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Project.
Abstract (Originalsprache)
Background
A considerable proportion of patients with early-stage lung adenocarcinoma (esLUAD) experience recurrence after curative resection, highlighting the need for improved biomarkers. Current biomarkers such as PD-L1 and tumor mutational burden (TMB) have limited predictive utility in early-stage disease. Through an unbiased screening approach, endoplasmic reticulum oxidoreductase 1α (ERO1A) was identified as a candidate gene for further investigation.
Methods
Multi-omics data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were integrated. Machine learning algorithms (least absolute shrinkage and selection operator (LASSO), random forest (RF), support vector machine (SVM)) were employed to identify core prognostic genes. Functional enrichment, immune microenvironment analysis, and drug sensitivity prediction were conducted. Key findings were validated using immunohistochemistry (IHC) in an independent institutional cohort.
Results
ERO1A was identified as a robust, independent predictor of poor overall and recurrence-free survival in esLUAD. It was significantly upregulated in tumors and associated with enhanced proliferative pathways. Paradoxically, high ERO1A expression correlated with an immune-activated tumor microenvironment, characterized by enriched CD8 + T cell infiltration, reduced M2 macrophages, and increased mature tertiary lymphoid structures. ERO1A-high tumors exhibited elevated TMB and PD-L1 levels, and were associated with superior response to immune checkpoint inhibitors in validation cohorts. Bioinformatic analysis suggested that ERO1A-high tumors might exhibit resistance to conventional chemotherapy while showing potential sensitivity to epidermal growth factor receptor (EGFR)-targeted therapies, though this was not confirmed in clinical validation.
Conclusions
ERO1A expression stratifies lung adenocarcinoma (LUAD) into distinct subsets with divergent therapeutic implications. It represents a promising biomarker for prognostic stratification and immunotherapy selection, supporting its potential clinical utility in guiding peri-operative therapy decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
- Department of Thoracic Surgery, Guangzhou First People's Hospital, Guangdong Medical University, Guangzhou, China.
- Center for Medical Research on Innovation and Translation, Guangzhou, China.
ORCID-Profile: Wangyu Chen
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangzhou Municipal Science and Technology Project
Zitieren
APA
Chen, W., Li, H., Zeng, J., Xie, G., Chen, Z., Xu, X., Bai, W., Xiao, G., & Xie, J. (2026). ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma. PeerJ, 14, e21347. https://doi.org/10.7717/peerj.21347
Vancouver
Chen W, Li H, Zeng J, Xie G, Chen Z, Xu X, et al. ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma. PeerJ. 2026;14:e21347. doi:10.7717/peerj.21347
BibTeX
@article{Chen2026,
author = {Chen, Wangyu and Li, Haiming and Zeng, Jie and Xie, Guijing and Chen, Zhibo and Xu, Xie and Bai, Wenjie and Xiao, Gang and Xie, Jianjiang},
title = {ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma},
journal = {PeerJ},
year = {2026},
volume = {14},
pages = {e21347},
doi = {10.7717/peerj.21347}
}
EUVIMED